Immune Pharmaceuticals Inc. (IMNP) Sees Significant Increase in Short Interest
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 1,079,060 shares, a growth of 38.7% from the August 31st total of 777,992 shares. Currently, 11.1% of the company’s stock are sold short. Based on an average daily trading volume, of 440,148 shares, the days-to-cover ratio is presently 2.5 days.
A hedge fund recently raised its stake in Immune Pharmaceuticals stock. Susquehanna International Group LLP grew its holdings in Immune Pharmaceuticals Inc. (NASDAQ:IMNP) by 41.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 69,805 shares of the biopharmaceutical company’s stock after purchasing an additional 20,488 shares during the quarter. Susquehanna International Group LLP owned about 0.69% of Immune Pharmaceuticals worth $215,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 3.39% of the company’s stock.
Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 1.52 on Thursday. The firm’s market cap is $16.07 million. Immune Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $5.02. The firm’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.90.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.